Zenas BioPharma, Inc. (ZBIO)
NASDAQ: ZBIO · Real-Time Price · USD
11.32
-0.79 (-6.52%)
Jun 12, 2025, 4:00 PM - Market closed
Zenas BioPharma Revenue
Zenas BioPharma had revenue of $10.00M in the quarter ending March 31, 2025. This brings the company's revenue in the last twelve months to $15.00M, down -70.00% year-over-year. In the year 2024, Zenas BioPharma had annual revenue of $5.00M, down -90.00%.
Revenue (ttm)
$15.00M
Revenue Growth
-70.00%
P/S Ratio
17.55
Revenue / Employee
$115,385
Employees
130
Market Cap
473.56M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 5.00M | -45.00M | -90.00% |
Dec 31, 2023 | 50.00M | - | - |
Dec 31, 2022 | - | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionZBIO News
- 11 hours ago - SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Zenas BioPharma - GlobeNewsWire
- 1 day ago - ZBIO Shareholders Have the Right to Lead the Zenas Biopharma, Inc. Securities Lawsuit - Contact the DJS Law Group to Discuss Your Rights - ZBIO - PRNewsWire
- 10 days ago - SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Zenas BioPharma - GlobeNewsWire
- 12 days ago - SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Zenas BioPharma - PRNewsWire
- 14 days ago - Zenas BioPharma to Present at the Jefferies Global Healthcare Conference - GlobeNewsWire
- 4 weeks ago - Reminder from Cohen Milstein: Zenas BioPharma (ZBIO) Lead Plaintiff Deadline in ZBIO Stock Drop Suit Approaching - GlobeNewsWire
- 4 weeks ago - Zenas BioPharma Reports First Quarter 2025 Financial Results and Provides Corporate Updates - GlobeNewsWire
- 4 weeks ago - INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Zenas BioPharma - GlobeNewsWire